Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.04 USD 0.04 ( 4.00%)
Last update at 2026-11-06T20:55:00Z
VOLUME
27348
Market Cap
3.75M

Momentum Score

…

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.99
Low
1.09
High
52 Week Price Range
1.00
Low
14.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cadrenal Therapeutics (NASDAQ: CVKD) is a publicly listed therapeutics company, but public disclosures about its business model, product pipeline and operations are limited. Because detailed information is not readily available, major long-term growth drivers are not clearly disclosed; investors may nevertheless be attracted to potential upside typical of small-cap life-sciences companies if development or partnership milestones are announced.
The primary risks are limited public disclosure and transparency, which create material uncertainty about the company's programs, as well as typical sector risks including regulatory, clinical and financing exposure.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-275.16%
Net Debt
-4.01M
ROCE
-491.76%
Diluted EPS TTM
-4.88

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Income before tax -13.24M -10.65M -8.36M -
Net income -13.24M -10.65M -8.36M -
Selling general administrative 9.35M 6.75M 3.55M -
Gross profit - -0.00M -0.00M -
Reconciled depreciation 0.01M 0.00M 0.00M -
Ebit -13.47M -10.65M -8.34M -2.95M
Ebitda -13.46M -10.65M -8.34M -
Depreciation and amortization 0.01M 0.00M 0.00M -
Operating income -13.46M -10.96M -7.63M -
Other operating expenses 13.46M 10.96M 7.63M -
Interest expense - 0.00M 0.02M -
Interest income 0.22M 0.31M 0.25M -
Net interest income 0.22M 0.31M 0.23M -
Income tax expense - - -0.17M -
Total revenue 0.00M 0.00M 0.00M -
Total operating expenses 13.46M 10.96M 7.63M -
Cost of revenue - 0.00M 0.00M -
Total other income expense net 0.22M 0.31M -0.72M -
Net income from continuing ops -13.24M -10.65M -8.36M -
Net income applicable to common shares - - - -7.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total assets 4.33M 10.12M 8.52M 0.78M
Other current assets 0.31M 0.06M 0.09M 0.70M
Total liab 1.59M 2.68M 0.83M 6.33M
Total stockholder equity 2.74M 7.44M 7.69M -5.55M
Other current liab 0.94M 1.18M 0.64M 0.86M
Common stock 0.00M 0.00M 0.01M 0.01M
Capital stock 0.00M 0.00M 0.01M 0.01M
Retained earnings -38.96M -25.72M -15.07M -6.71M
Other liab - - - 4.42M
Other assets - - - 0.01M
Cash 4.01M 10.02M 8.40M 0.03M
Total current liabilities 1.59M 2.68M 0.83M 1.33M
Net debt -4.01M -10.02M -8.38M 0.61M
Short term debt - - 0.02M 0.07M
Short long term debt - - - 0.04M
Short long term debt total - - 0.02M 0.64M
Other stockholder equity 41.70M 33.16M 22.75M 1.15M
Property plant equipment - - - 0.04M
Total current assets 4.32M 10.11M 8.49M 0.73M
Net tangible assets - - - -5.55M
Net receivables 0.01M 0.04M - -
Long term debt - - - 0.55M
Accounts payable 0.65M 1.50M 0.17M 0.40M
Non currrent assets other 0.00M 0.00M 0.00M -0.53M
Non current assets total 0.01M 0.01M 0.03M 0.05M
Capital lease obligations - 0.00M 0.02M 0.04M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Type yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Investments - -0.01M -0.00M -
Change to liabilities - - - 0.44M
Total cashflows from investing activities -0.01M -0.01M -0.00M -0.00M
Net borrowings - 0.00M -0.25M 1.34M
Total cash from financing activities 6.60M 8.98M 11.90M 1.35M
Change to operating activities - - - 0.22M
Net income -13.24M -10.65M -8.36M -7.32M
Change in cash -6.01M 1.62M 8.37M 0.04M
Begin period cash flow 10.02M 8.40M 0.03M -
End period cash flow 4.01M 10.02M 8.40M -
Total cash from operating activities -12.60M -7.36M -3.53M -1.31M
Issuance of capital stock 7.16M 5.14M 11.90M -
Depreciation 0.01M 0.00M 0.00M 0.00M
Other cashflows from investing activities -0.01M -0.01M - -
Change to account receivables 0.03M - - -
Sale purchase of stock -0.29M 0.00M - -
Other cashflows from financing activities -0.27M 3.84M 0.25M -
Change to netincome - - - 5.27M
Capital expenditures 0.01M 0.01M 0.00M 0.00M
Change in working capital -1.31M 1.87M 0.14M -
Stock based compensation 1.94M 1.42M 0.71M -
Other non cash items -1.31M -0.00M 3.97M -
Free cash flow -12.60M -7.36M -3.53M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
CVKD
Cadrenal Therapeutics, Inc. Common Stock		 0.04
4.00%		 1.04 - - - 0.92 0.21
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

822 A1A North, Ponte Vedra, FL, United States, 32082

904 300 0701

https://www.cadrenal.com

5

Name Title Year Born
Dr. Douglas W. Losordo FACC, FAHA, M.D. Chief Medical Officer 1958
Mr. Quang X. Pham Chairman & CEO 1965
Mr. Matthew K. Szot CPA, CPA Chief Financial Officer 1974
Mr. Jeffrey Cole Chief Operating Officer NA
Mr. Matthew K. Szot CPA Co-Founder & CFO 1974
Dr. James J. Ferguson FACC, M.D. Chief Medical Officer 1954
Mr. Jeffrey Cole Chief Operating Officer 1968
Dr. Matthew Boxer M.B.A., Ph.D. Executive Vice President of Corporate Development NA
Mr. John P. Sharp CPA Interim CFO & Principal Accounting Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…